

The perception of neuro wellness is changing

An emerging
Market Opportunity:

~1 Billion


People affected by mental
health disorders worldwide¹

\$2.5 Trillion

Global economic cost
from mental disorders²

**Capital is actively
pursuing the
neurowellness
industry**

Compass Pathways
became the first
company to be publicly
traded north of \$1B



2021
\$730M
invested across
51 deals

\$180 Billion

Total behavioral healthcare
market by 2026³

~\$10 Billion

Psychedelic medicines
market by 2027⁴

**Promising early research on the power of psychedelics and a growing
social acceptance has the potential to transform mental health:**



>100

Ongoing FDA
clinical trials



48

Publicly traded
psychedelic companies



5

States with partial
decriminalization
(incl. Washington, D.C.)



6

Academic institutions
with psychedelic
research centers

¹ Global Health Data Exchange <http://ghdx.healthdata.org/gbd-results-tool>

² <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007565/>

³ GMI Research <https://www.gmi-research.com/report/global-behavioral-health-market-by-services-type/>

⁴ Data Bridge Market Research <https://www.databridgemarketresearch.com/toc/?dbmr=us-psychedelic-drugs-market>



Invest in the Mind

CONTACT

Evan Schnurmacher
Portfolio Analyst
evan@phytopartners.com
March 2022

The Phyto Approach

This nascent industry presents a unique investment opportunity for considerable growth and innovation as the market continues to scale. Phyto Partners has identified three core pillars driving this growth:

Developers of Therapeutics

for mental health disorders
and other related illnesses

Research Tools and Organizations

devoted to the investigation of
new psychedelic technologies

Ancillary Companies

supporting the growth of
the psychedelics industry

The Investment Opportunity is Now

**Lack of effective treatments
for mental health disorders
represents a significant unmet
need for patients worldwide.**

- Regulatory pathways and lengthy FDA approval processes will require near-term investments in early clinical and preclinical programs.
- Numerous clinical trials are already underway, with the first FDA approvals expected as early as 2023.

QUICK FUND FACTS

Fund size \$2.5 – \$25M

First close Feb 28th, 2022

\$250,000 minimum

8% Preferred Return*

4 year Investment Period

10 year fund Life*

Management Fee 2% annually

GP 20% Incentive Fee

Manager Phyto Advisors

Administrator NAV Consulting

Legal Counsel Robinson Brog

GP and Affiliates >
10% of Capital in Fund

Open to ACCREDITED
Investors

Track Record of Success

Phyto Partners provides debt and equity capital to privately held cannabis companies. Since June 2015, Phyto Partners has deployed capital into 30 distinct portfolio companies across the value chain of the cannabis industry, including education, branded products, agriculture technology, point of sale software, biotechnology, and more.

Through our capital resources and broad network of industry relationships, we offer our companies financial sponsorship, critical strategic support, and business development assistance. Phyto Partners brings strategic Value Add to each portfolio company by actively introducing companies to potential customers, investors, strategic advisors, and M&A targets and suitors employing our ecosystem and network to help our portfolio companies win.

Our portfolio companies are able to leverage off one another and collaborate to execute successful business plans. Our advisors and industry relationships bring together the knowledge and expertise to help our portfolio companies thrive in the dynamic and fast growing psychedelics industry.